Working… Menu

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04642937
Recruitment Status : Recruiting
First Posted : November 24, 2020
Last Update Posted : March 2, 2021
Information provided by (Responsible Party):
OX2 Therapeutics

Brief Summary:
This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma (GBM) in adults.

Condition or disease Intervention/treatment Phase
Glioblastoma Drug: Treatment with hP1A8 Phase 1

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
Actual Study Start Date : December 1, 2020
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: hP1A8
Up to 3 dose levels of hP1A8 will be tested with a Dose Level -1 in the event of toxicity. The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort.
Drug: Treatment with hP1A8
Treatment with hP1A8

Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) of hP1A8 when administered with imiquimod and GBM6-AD [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Incidence of serious adverse events (SAEs) [ Time Frame: 12 months ]
  2. Time to progression (TTP) [ Time Frame: 24 months ]
  3. Progression free survival (PFS) [ Time Frame: 24 months ]
  4. Overall survival (OS) [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 18 years and older.
  • Confirmed diagnosis of GBM.
  • Radiographically or histologically proven progression or recurrence of disease at any time after standard of care therapy (radiation, temozolomide, with or without a tumor treatment field device).
  • Tumor debulking or biopsies may be performed to clinical trial enrollment if indicated and feasible.

Exclusion Criteria:

  • Bevacizumab or targeted therapy within 45 days of enrollment.
  • Intercurrent immune system disorder such as hypoimmunity (marrow failure, HIV) or hyperimmunity (autoimmune disease).
  • Unable to complete a standard upfront course of chemoradiotherapy due to disease progression or intolerance of therapy.
  • History of Gliadel water, GammaTile or other implanted therapeutic agent.
  • Concurrent use of tumor treatment field devices (e.g. Optune).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04642937

Layout table for location contacts
Contact: Elizabeth Neil, MD 612-625-1969
Contact: Masonic Cancer Center Cancer information nurse line 612-624-2620

Layout table for location information
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Elizabeth Neil, MD    612-625-1969   
Sponsors and Collaborators
OX2 Therapeutics
Layout table for additonal information
Responsible Party: OX2 Therapeutics Identifier: NCT04642937    
Other Study ID Numbers: CRPC #2017LS096
First Posted: November 24, 2020    Key Record Dates
Last Update Posted: March 2, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue